In our gastrointestinal cancer quiz, you’ll get to test your knowledge on the current treatment options for patients with gastric/gastroesophageal junction cancer, and how the disease impacts patients worldwide.
How common is gastric and gastroesophageal junction (G/GEJ) cancer worldwide?
a. It is the fifth leading cause of death
b. It is the second leading cause of death
c. It is the third leading cause of death
d. None of the above
FDA Issues CRL for Zolbetuximab in Advanced CLDN18.2+ Gastric Cancer
January 9th 2024The FDA cannot approve the application for zolbetuximab in advanced or metastatic gastric or gastroesophageal junction adenocarcinoma due to unresolved issues following a pre-license inspection of a third-party manufacturing site.
Quiz: Detecting Very Early Recurrence After Liver Resection for Intrahepatic Cholangiocarcinoma
August 10th 2020In our liver cancer quiz, you’ll get a chance to test your knowledge on recurrence following resection in patients with intrahepatic cholangiocarcinoma and the new tools being developed to aid in treating this patient population.